William F. Keane
#135,488
Most Influential Person Now
William F. Keane's AcademicInfluence.com Rankings
William F. Keanephilosophy Degrees
Philosophy
#6807
World Rank
#9910
Historical Rank
Logic
#3913
World Rank
#5141
Historical Rank

Download Badge
Philosophy
William F. Keane's Degrees
- Doctorate Medicine University of California, San Francisco
Why Is William F. Keane Influential?
(Suggest an Edit or Addition)William F. Keane's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- K/DOQI clinical practice guidelines for chronic kidney disease (2002) (8858)
- Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. (2001) (5071)
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. (2004) (956)
- Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy (2004) (746)
- Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. (1984) (702)
- Nephropathy in diabetes. (2004) (698)
- Effect of Antihypertensive Therapy on the Kidney in Patients with Diabetes: A Meta-Regression Analysis (1993) (622)
- Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. (1999) (596)
- Prevention of diabetic renal disease with special reference to microalbuminuria (1995) (567)
- Association between active Wegener's granulomatosis and anticytoplasmic antibodies. (1989) (547)
- The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. (2003) (517)
- Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. (1988) (428)
- Adult Peritoneal Dialysis-Related Peritonitis Treatment Recommendations: 2000 Update (2000) (426)
- Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. (2000) (341)
- Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. (1995) (330)
- Pharmacokinetics of vancomycin in patients with various degrees of renal function (1984) (327)
- Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. (1996) (324)
- Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. (2007) (305)
- Pharmacologic Treatment of Hyperlipidemia Reduces Glomerular Injury in Rat 5/6 Nephrectomy Model of Chronic Renal Failure (1988) (294)
- Renal injury of diet-induced hypercholesterolemia in rats. (1990) (280)
- The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. (1992) (271)
- Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). (2003) (260)
- A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. (2001) (260)
- Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. (2004) (221)
- Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. (1988) (220)
- Effects of genetic obesity on renal structure and function in the Zucker rat. (1985) (220)
- Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. (1997) (204)
- Lipids and the kidney. (1994) (201)
- Lovastatin inhibits proliferation of rat mesangial cells. (1993) (182)
- Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. (1987) (179)
- Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. (2006) (179)
- Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? (1996) (178)
- Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. (1985) (175)
- Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. (1989) (165)
- Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. (2005) (163)
- Proteinuria: its clinical importance and role in progressive renal disease. (2000) (159)
- Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis. (1981) (158)
- Glomerular hemodynamic and structural alterations in experimental diabetes mellitus (1988) (158)
- Recent advances in statins and the kidney. (1999) (156)
- Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. The Ad Hoc Advisory Committee on Peritonitis Management. International Society for Peritoneal Dialysis. (1993) (143)
- The assessment of risk factors in 462 patients with acute renal failure. (1985) (142)
- The role of lipids in renal disease: future challenges. (2000) (141)
- Peritoneal macrophages and opsonins: antibacterial defense in patients undergoing chronic peritoneal dialysis. (1983) (141)
- INCIDENCE AND TYPE OF INFECTIONS OCCURRING IN 445 CHRONIC HEMODIALYSIS PATIENTS (1977) (138)
- The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) (2000) (135)
- Glomerular mesangium: its function and relationship to angiotensin II. (1985) (134)
- Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis. (1994) (133)
- Hyperlipidemia and progressive renal disease. (1991) (132)
- Current concepts in the management of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. (1987) (128)
- Opsonic deficiency of peritoneal dialysis effluent in continuous ambulatory peritoneal dialysis. (1984) (126)
- Reviews and Original Articles (1996) (125)
- Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity. (1987) (122)
- Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies. (1985) (112)
- Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. (1992) (104)
- Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. (2001) (102)
- Lovastatin retards the progression of established glomerular disease in obese Zucker rats. (1993) (102)
- Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. (1998) (97)
- Radiation-induced renal disease. A clinicopathologic study. (1976) (97)
- Mechanism of Escherichia coli alpha-hemolysin-induced injury to isolated renal tubular cells. (1987) (95)
- Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. (1984) (95)
- Protective Effect of HMG-CoA Reductase Inhibitor on Experimental Renal Ischemia-Reperfusion Injury (2002) (92)
- Relationship among altered glomerular barrier permselectivity, angiotensin II, and mesangial uptake of macromolecules. (1985) (92)
- Early glomerular changes in rats with dietary-induced hypercholesterolemia. (1995) (91)
- Hyperlipidemia and the progression of renal disease. (1988) (90)
- Lipids and the kidney. (1990) (88)
- Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids (1984) (87)
- Determinants of glomerular filtration and plasma flow in experimental diabetic rats. (1981) (87)
- Role of hypertension in progressive glomerular immune injury. (1985) (87)
- Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. (2003) (86)
- Disposition of Gabapentin in Anuric Subjects on Hemodialysis (1995) (85)
- Correlation of office and ambulatory blood pressure measurements with urinary albumin and N-acetyl-beta-D-glucosaminidase excretions in essential hypertension. (1988) (85)
- Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis. (2013) (84)
- Lipid abnormalities in end stage renal disease. (1998) (80)
- Renal injury in obese Zucker rats: glomerular hemodynamic alterations and effects of enalapril. (1992) (80)
- Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats. (1989) (80)
- Treatment Recommendations 1993 Update (1993) (80)
- Consensus Development Conference on the Diagnosis and Management of Nephropathy in Patients with Diabetes Mellitus (1994) (78)
- Identification of persons at high risk for kidney disease via targeted screening: the NKF Kidney Early Evaluation Program. (2003) (78)
- Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. (2003) (76)
- Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. (2000) (75)
- Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. (1995) (74)
- Adriamycin-induced chronic proteinuria: a structural and functional study. (1985) (70)
- Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. (2001) (70)
- Oxidative modification of low-density lipoproteins by mesangial cells. (1993) (68)
- Lipids and progressive renal injury. (1989) (67)
- Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. (1996) (64)
- The central role of nuclear factor-κB in mesangial cell activation (1999) (60)
- Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia. (1992) (60)
- The pharmacokinetics of losartan in renal insufficiency (1995) (59)
- Antimicrobial Treatment of Peritonitis Associated with Continuous Ambulatory Peritoneal Dialysis (1991) (57)
- The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome. (1990) (56)
- The renin-angiotensin system in the type II diabetic obese Zucker rat. (1993) (56)
- Proteinuria and cardiovascular disease. (2001) (54)
- CAPD Related Peritonitis Management and Antibiotic Therapy Recommendations Travenol Peritonitis Management Advisory Committee (1987) (53)
- Antimicrobial activities of dialysate-elicited and resident human peritoneal macrophages (1985) (52)
- Effects of Nephron Loss on Glomerular Hemodynamics and Morphology in Diabetic Rats (1986) (51)
- Lipophilic statins induce apoptosis of human vascular smooth muscle cells. (1999) (50)
- Perinephric abscess in patients with polycystic kidney disease undergoing chronic hemodialysis. (1979) (49)
- Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis Treatment Recommendations: 1989 Update (1989) (48)
- Irreversible acute renal failure in idiopathic nephrotic syndrome. (1976) (46)
- Hypertension, hyperlipidemia, and renal damage. (1993) (44)
- Effects of cyclosporine on the isolated perfused rat kidney. (1987) (44)
- Cholesterol-Lowering Effects oHypercholesterolemiain Patients With Mild to Moderate Hypercholesterolemia (1992) (44)
- Human peritoneal macrophage phagocytic, killing, and chemiluminescent responses to opsonized Listeria monocytogenes (1983) (43)
- Experimental pyelonephritis. XIV. Pyelonephritis in normal mice produced by inoculation of E. coli into the bladder lumen during water diuresis. (1967) (42)
- Lipids in progression of renal disease. (1997) (42)
- Survival and rehabilitation of patients on home hemodialysis. Five years' experience. (1973) (41)
- Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. (1985) (41)
- Lipid-lnduced Glomerular Injury (1994) (41)
- Age is a determinant of the glomerular morphologic and functional responses to chronic nephron loss. (1985) (40)
- The role of altered lipid metabolism in the progression of renal disease: experimental evidence. (1991) (40)
- Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? (1992) (40)
- Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. (2005) (39)
- Impact of dietary fatty acid supplementation on renal injury in obese Zucker rats. (1991) (38)
- Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. (1996) (37)
- Unilateral Shwartzman reaction: cortical necrosis in one kidney following in vivo perfusion with endotoxin. (1977) (36)
- Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency. (1988) (36)
- Glomerular permeability to neutral and anionic dextrans in experimental diabetes. (1982) (35)
- Glomerular hemodynamic and structural correlations in long-term experimental diabetic rats. (1984) (35)
- Host Defense Mechanisms of the Peritoneal Cavity and Continuous Ambulatory Peritoneal Dialysis (1984) (34)
- Enhancement of endotoxin-induced isolated renal tubular cell injury by toxic shock syndrome toxin 1. (1986) (34)
- Host Defenses and Infectious Complications in Maintenance Hemodialysis Patients (1996) (33)
- Hyperlipidemia in the nephrotic syndrome. (1990) (33)
- Mesangial function in ureteral obstruction in the rat. Blockade of the efferent limb. (1979) (32)
- Polyamino acid enhancement of bacterial phagocytosis by human polymorphonuclear leukocytes and peritoneal macrophages (1984) (32)
- Intravascular and extracellular volumes in the diabetic rat. (1981) (30)
- The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis. (1995) (30)
- Beta-endorphin stimulates human polymorphonuclear leukocyte superoxide production via a stereoselective opiate receptor. (1987) (30)
- Intestinal and Hepatic Cholesterol Synthesis in the Alloxan Diabetic Rat 1 (1982) (30)
- Intracellular survival of Candida albicans in peritoneal macrophages from chronic peritoneal dialysis patients. (1986) (30)
- Lipid abnormalities in patients with chronic kidney disease. (2011) (30)
- Diabetic nephropathy. (2003) (30)
- Renal protective effects of angiotensin-converting enzyme inhibition. (1990) (30)
- The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rats. (1995) (28)
- The mevalonate pathway: importance in mesangial cell biology and glomerular disease. (1993) (28)
- Cefotaxime and desacetyl cefotaxime kinetics in renal impairment (1985) (28)
- Hemodialysis elimination rates and clearance of gentamicin and tobramycin (1984) (28)
- The central role of nuclear factor-kappa B in mesangial cell activation. (1999) (27)
- Successful renal transplantation in progressive systemic sclerosis. (1976) (27)
- Immunosuppressive effects of leflunomide in experimental chronic vascular rejection. (1995) (26)
- The national epidemic of chronic kidney disease (2001) (26)
- Lipids and progressive renal failure. (1996) (26)
- Metabolic pathogenesis of cardiorenal disease. (2001) (26)
- Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study (2006) (26)
- Continuous ambulatory peritoneal dialysis (CAPD) peritonitis treatment recommendations: 1989 update. The Ad Hoc Advisory Committee on Peritonitis Management. (1989) (25)
- Disposition of Famotidine in Renal Insufficiency (1987) (25)
- Pharmacokinetics and Blood Pressure Response of Losartan in End-Stage Renal Disease (2000) (25)
- Impaired mesangial clearance of macromolecules in rats with chronic mesangial ferritin-antiferritin immune complex deposition. (1980) (25)
- High protein intake accelerates glomerulosclerosis independent of effects on glomerular hemodynamics. (1990) (24)
- Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies (2007) (24)
- Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus. (1997) (24)
- Lipids and the progression of renal disease. (1990) (23)
- Risk factors for glomerular injury in rats with genetic hypertension. (1989) (23)
- [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. (2001) (23)
- Recommendations for reducing the high morbidity and mortality of United States maintenance dialysis patients. The National Kidney Foundation. (1994) (22)
- Therapeutic implications of lipid-lowering agents in the progression of renal disease. (1989) (22)
- The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: a double-blind, placebo-controlled trial in patients with esrd. (2001) (22)
- Assessment of structure and function in progressive renal disease. (1997) (22)
- Lipids and progressive renal disease: the cardio-renal link. (1999) (22)
- The role of lipid abnormalities in the pathogenesis of chronic, progressive renal disease. (1991) (20)
- Renal cell cytokine production stimulates HIV-1 expression in chronically HIV-1-infected monocytes. (1998) (20)
- The Future of Clinical Trials in Chronic Renal Disease: Outcome of an NIH/FDA/Physician Specialist Conference (2000) (20)
- Modulatory effects of β-endorphin on interferon-γ production by cultured peripheral blood mononuclear cells: Heterogeneity among donors and the influence of culture medium (1988) (20)
- Opsonization of Legionella pneumophila in human serum: key roles for specific antibodies and the classical complement pathway. (1985) (19)
- The obese Zucker rat model of glomerular injury in type II diabetes. (1987) (19)
- Host Defense Mechanisms of the Peritoneal Cavity and Continuous Ambulatory Peritoneal Dialysis (1991) (19)
- Importance of geranylgeranyl pyrophosphate for mesangial cell DNA synthesis. (1999) (19)
- Mononuclear phagocytic system stimulation. Protective role from glomerular immune complex deposition. (1981) (19)
- Adjunctive therapy with intravenous human immunoglobulin G improves survival of patients with acute renal failure. (1991) (18)
- Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL Study. (2005) (18)
- Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency (1991) (17)
- Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure (1993) (17)
- The effect of famotidine on renal function in patients with renal insufficiency. (1987) (16)
- Pharmacokinetics of Zileuton and Its Metabolites in Patients with Renal Impairment (1997) (16)
- Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis. (1994) (15)
- Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. (2004) (15)
- Diabetes in the elderly population. (2000) (14)
- Kidney disease and cardiovascular disease: implications of dyslipidemia. (2005) (14)
- Pharmacokinetics of Tazobactam M1 Metabolite After Administration of Piperacillin/Tazobactam in Subjects with Renal Impairment (1994) (14)
- Renal disease in cryoglobulinemia type II: response to therapy. A case report and review of the literature. (1982) (13)
- Determinants of glomerular mesangial localization of immune complexes. Role of endothelial fenestrae. (1981) (13)
- Treatment of hyperlipidemia in chronic progressive renal disease. (1993) (13)
- Central role of the transcription factor nuclear factor-kappa B in mesangial cell production of chemokines. (1997) (13)
- The role of lipids in progressive glomerular disease. (1987) (13)
- Antihypertensive Therapy with Once‐daily Administration of Terazosin, a New Alpha1‐adrenergic‐receptor Blocker (1985) (13)
- Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables. (2017) (12)
- Isoprenoids and Ras: potential role in chronic rejection. (1995) (12)
- Glomerular hemodynamic effects of dietary polyunsaturated fatty acid supplementation. (1991) (12)
- Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing (1989) (12)
- Suprofen-induced uricosuria. A potential mechanism for acute nephropathy and flank pain. (1988) (12)
- Pathogenesis of Atherosclerosis (1964) (11)
- Higher haematocrit levels: do they improve patient outcomes, and are they cost effective? (1998) (11)
- Effects of carbohydrate restriction on renal injury in the obese Zucker rat. (1986) (10)
- Effect of long-term clofibric acid treatment on serum and tissue lipid and cholesterol levels in obese Zucker rats. (1987) (9)
- Human peritoneal macrophage cytotoxicity mediated by cytophilic IgG. (1983) (9)
- Losartan: lessons learned from the RENAAL study (2006) (9)
- Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells. (1999) (9)
- Lipid-induced glomerular injury. (1994) (9)
- Alterations in glomerular proteoglycan metabolism in experimental non-insulin dependent diabetes mellitus. (1993) (9)
- The effects of chronic mesangial immune injury on glomerular function. (1980) (9)
- Risk factors for nephropathy and cardiovascular disease in diabetic Northern Minnesota American Indians. (1996) (9)
- Cefsulodin pharmacokinetics in patients with various degrees of renal function (1983) (8)
- Regulation of mesangial cell proliferation by the mevalonate pathway. (1997) (8)
- Renal effects of angiotensin II: modulation by calcium and cyclooxygenase products. (1986) (8)
- The long-term tolerability of enalapril in hypertensive patients with renal impairment. (1997) (7)
- Lipids, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, and progression of renal failure. (1997) (7)
- Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30MGKG−1 (1992) (7)
- The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy (2012) (7)
- Acute glomerulonephritis. A clinical overview. (1984) (7)
- Fish oil diet decreases prostacyclin and increases resistance in isolated rat kidneys. (1989) (6)
- Effects of immunosuppressive agents, cyclosporin A, FK-506 and genistein on the sysnthesis of 5-lipoxygenase metabolite(s) of arachidonic acid by human mononuclear cells (1992) (6)
- Role of lipid peroxidation in the inhibition of mononuclear cell proliferation by normal lipoproteins. (1991) (6)
- Derangement of lipid metabolism and its management in renal transplant patients. (1997) (6)
- Host Defense Mechanisms in Chronic Ambulatory Peritoneal Dialysis—Associated Peritonitis (1989) (6)
- Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease (1992) (6)
- Treatment of type 2 diabetic patients with kidney disease with AT1-receptor antagonists: lessons from recent trials (2002) (5)
- Pharmacokinetics of MAT9001, an Omega‐3 Fatty Acid Medication, Compared with Eicosapentaenoic Acid Ethyl Esters in Hypertriglyceridemic Subjects (2016) (5)
- Infectious Complications in Maintenance Dialysis Patients (1979) (5)
- Angiotensin-Converting Enzyme Inhibitors in Chronic Renal Failure (2012) (4)
- Comparison of antihypertensive, renal hemodynamic, and humoral effects of pinacidil and hydralazine monotherapy. (1987) (4)
- Causes, Consequences, and Treatment of Hyperlipidemia in Patients with Renal Disease (1990) (4)
- Lack of pharmacodynamic interaction between pentoxifylline and warfarin in the rat. (1986) (4)
- Mild hypothermia gives better functional preservation than cold or normothermic perfusion of rat kidneys. (1990) (4)
- Effect of lipids on glomerular injury and progression of renal disease. (1994) (4)
- Renal injury in obese Zucker rats (1992) (3)
- Renal diagnostic testing: past, present and future. (1996) (3)
- A Large Step in the Treatment of Peritonitis in Peritoneal Dialysis Patients (1996) (3)
- Progression of renal disease (1994) (3)
- Degenerative and age-related changes in the x-irradiated kidney of the rat. (1978) (3)
- Hypertension adverse experiences among osteoarthritis patients treated with rofecoxib, celecoxib, or acetaminophen in the VACT trials (2003) (2)
- Modulatory effects of beta-endorphin on interferon-gamma production by cultured peripheral blood mononuclear cells: heterogeneity among donors and the influence of culture medium. (1988) (2)
- Chronic renal allograft failure (1995) (2)
- Treatment of Peritonitis: Update or New Course (2000) (2)
- Glomerular, mesangial and tubular function in mercury chloride (HgCl2) acute renal failure (ARF) (1977) (2)
- Isoprenoids, Ras and proliferative glomerular disease. (1997) (2)
- Experimental pyelonephritis in the mouse (1968) (1)
- Analytical specificity of commercially available methods for serum phenytoin determination. (1984) (1)
- Peritonitis during continuous ambulatory peritoneal dialysis: the role of host defense mechanisms. (1984) (1)
- The Obese Zucker Rat Model of Chronic, Progressive Glomerular Injury (1993) (1)
- OR-83: Hypertension among osteoarthritis patients treated with rofecoxib, celecoxib, or acetaminophen: an analysis of the data from the pooled VACT studies (2003) (1)
- Lipids and Renal Disease (1991) (1)
- Effects of Lipid Manipulations in Chronic Renal Failure (1991) (1)
- CHAPTER 67 – Management of Hyperlipidemia in Chronic Dialysis Patients (2008) (1)
- The Influence of Hemodynamic Factors upon Mesangial Kinetics of Macromolecules (1983) (1)
- Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis and Exit-Site Infections: Challenges for the Future (1989) (1)
- Cefsulodin pharmacokinetics during hemodialysis. (1982) (1)
- Direct effects of altered temperature on renal structure and function. (1988) (1)
- Polymorphonuclear leukocyte, T-lymphocyte, and natural killer cell activities in elderly nursing home residents (1986) (1)
- DISPOSITION OF MISOPROSTOL AND ITS ACTIVE METABOLITE IN IMPAIRED HEPATIC FUNCTION (1994) (1)
- Effects of cyclosporin A, FK-506 and genistein on IL-6, IL-8 production and gene expression by human mononuclear cells (1993) (1)
- Tobramycin‐induced hearing loss in a patient with end‐stage renal disease (1983) (1)
- Lipids and progressive renal failure. (1996) (1)
- Editors JORDAN J. COHEN (1994) (0)
- Antibiotics: Vancomycin (1989) (0)
- ambulatory peritoneal dialysis fluids. Bacterial growth and killing in chronic (2013) (0)
- Diagnostics and techniques. (1996) (0)
- Glomerular haemodynamic function in long-term diabetic rats with systemic hypertension (1986) (0)
- Effects of Dietary Fatty Acids on Experimental Renal Disease (1993) (0)
- Human mononuclear cell proliferation, but not interleukin-6 production, is dependent on isoprenoid products of mevalonate metabolism (1994) (0)
- Role of lipid peroxidation in the inhibition of mononuclear cell proliferation by normal I i poproteins (2002) (0)
- Relationship between glomerular filtration rate and mesangial kinetics in mercury chloride acute renal failure (1976) (0)
- Peritonitis and Other Complications (1998) (0)
- THE ROLE OF PROTEINURIA IN THE DIAGNOSIS AND TREATMENT OF TYPE 2 DIABETES (2004) (0)
- Quiz of the Month, Answer / Publisher’s Note (1984) (0)
- Effects of Eicosapentaenoic Acid Plus Docosapentaenoic Acid and Eicosapentaenoic Acid Alone on Fasting and Postprandial Lipids (2016) (0)
- Lipids and the Kidney (Preliminary Pages) (1997) (0)
- Combined RES stimulation and immunosuppression in glomerular immune complex (IC) injury (1982) (0)
- Angiotensin Converting Enzyme Inhibitors and Progressive Renal Insufficiency (2020) (0)
- Changing the course of diabetic renal disease by antihypertensive treatment: A meta-regression analysis of published data (1992) (0)
- NephrologyDialysis Transplantation Lovastatin inhibits lipopolysaccharide-induced NF-#cB activation in human mesangial cells (2005) (0)
- Modulation of renal injury by lipids: Experimental and clinical data (1993) (0)
- The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment (2004) (0)
- Renal effects of angiotensin converting enzyme inhibitors: Nondiabetic chronic renal disease (2005) (0)
- Survival in mercury chloride (HgCl2) induced acute renal failure (ARF) and its relationship to the maintenance of urinary kallikrein excretion (UKE) (1977) (0)
- [Hyperlipidemia and nephropathy: cause or consequence?]. (1995) (0)
- About the cover illustration: Focal glomerular sclerosis with lipid-filled vacuoles (1997) (0)
- The role of lipid abnormalities in renal and vascular injury (1992) (0)
- Progression of renal disease : clinical patterns, therapeutic options, and lessons from clinical trials (1997) (0)
- [The 32nd Western/Eastern regional meeting, Japanese Society of Nephrology. Wakayama prefecture, Tokyo, Japan. October 4-5, 2002. Abstracts]. (2002) (0)
- The renal cardiovascular axis: new diagnostic insights (1997) (0)
- P-527: Effect of rofecoxib vs. naproxen on hypertension and edema related events: a multivariate analysis involving 5557 patients from the advantage trial (2002) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With William F. Keane?
William F. Keane is affiliated with the following schools: